Study Finds Paxlovid Treatment Does Not Reduce Risk of Long COVID

A team of researchers from UC San Francisco has found that Paxlovid (Nirmatrelvir-ritonavir) did not reduce the risk of developing long COVID for vaccinated, no

Related Keywords

San Francisco ,California ,United States ,Oakland ,Carmen Isasi ,Gregorym Marcus ,Michaelj Peluso ,Feng Lin ,Matthew Durstenfeld ,Noahd Peyser ,Markj Pletcher ,Steveng Deeks ,Alexisl Beatty ,Timothyj Henrich ,Jeffreye Olgin ,Twitter ,Facebook ,Health On Facebook ,Melinda Gates Foundation ,Eureka Research Platform ,University Of California ,Youtube ,Outcomes Research Institute ,Science Study ,Patient Centered Outcomes Research Institute ,Langley Porter Psychiatric Hospital ,